Product Description
ANC-501 is a drug candidate for the treatment of major depressive disorder from Aditum Bio. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05439603)
Mechanisms of Action: V1b Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Depressive Disorder, Major
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ANC501D0005 | P2 |
Active, not recruiting |
Depressive Disorder, Major |
2023-09-25 |